Shakil Md Salman, Niloy Mahruba Sultana, Mahmud Kazi Mustafa, Kamal Mohammad Amjad, Islam Md Asiful
Department of Mathematics and Natural Sciences, Brac University, 66 Mohakhali, Dhaka 1212, Bangladesh.
Department of Pharmacology & Toxicology, University of Otago, Dunedin 9016, New Zealand.
Cancers (Basel). 2022 Jun 21;14(13):3047. doi: 10.3390/cancers14133047.
Hematological malignancies (HMs) are a heterogeneous group of blood neoplasia generally characterized by abnormal blood-cell production. Detection of HMs-specific molecular biomarkers (e.g., surface antigens, nucleic acid, and proteomic biomarkers) is crucial in determining clinical states and monitoring disease progression. Early diagnosis of HMs, followed by an effective treatment, can remarkably extend overall survival of patients. However, traditional and advanced HMs' diagnostic strategies still lack selectivity and sensitivity. More importantly, commercially available chemotherapeutic drugs are losing their efficacy due to adverse effects, and many patients develop resistance against these drugs. To overcome these limitations, the development of novel potent and reliable theranostic agents is urgently needed to diagnose and combat HMs at an early stage. Recently, gold nanomaterials (GNMs) have shown promise in the diagnosis and treatment of HMs. Magnetic resonance and the surface-plasmon-resonance properties of GNMs have made them a suitable candidate in the diagnosis of HMs via magnetic-resonance imaging and colorimetric or electrochemical sensing of cancer-specific biomarkers. Furthermore, GNMs-based photodynamic therapy, photothermal therapy, radiation therapy, and targeted drug delivery enhanced the selectivity and efficacy of anticancer drugs or drug candidates. Therefore, surface-tuned GNMs could be used as sensitive, reliable, and accurate early HMs, metastatic HMs, and MRD-detection tools, as well as selective, potent anticancer agents. However, GNMs may induce endothelial leakage to exacerbate cancer metastasis. Studies using clinical patient samples, patient-derived HMs models, or healthy-animal models could give a precise idea about their theranostic potential as well as biocompatibility. The present review will investigate the theranostic potential of vectorized GNMs in HMs and future challenges before clinical theranostic applications in HMs.
血液系统恶性肿瘤(HMs)是一组异质性血液肿瘤,通常以血细胞生成异常为特征。检测HMs特异性分子生物标志物(如表面抗原、核酸和蛋白质组学生物标志物)对于确定临床状态和监测疾病进展至关重要。HMs的早期诊断并随后进行有效治疗,可以显著延长患者的总生存期。然而,传统和先进的HMs诊断策略仍然缺乏选择性和敏感性。更重要的是,市售的化疗药物由于不良反应而逐渐失去疗效,许多患者对这些药物产生耐药性。为了克服这些局限性,迫切需要开发新型强效且可靠的诊疗试剂,以便在早期诊断和对抗HMs。最近,金纳米材料(GNMs)在HMs的诊断和治疗方面显示出前景。GNMs的磁共振和表面等离子体共振特性使其成为通过磁共振成像以及癌症特异性生物标志物的比色或电化学传感来诊断HMs的合适候选材料。此外,基于GNMs的光动力疗法、光热疗法、放射疗法和靶向药物递送提高了抗癌药物或候选药物的选择性和疗效。因此,表面调谐的GNMs可用作敏感、可靠且准确的早期HMs、转移性HMs和微小残留病检测工具,以及选择性强效抗癌剂。然而,GNMs可能会导致内皮渗漏,从而加剧癌症转移。使用临床患者样本、患者来源的HMs模型或健康动物模型进行的研究,可以准确了解它们的诊疗潜力以及生物相容性。本综述将研究载体化GNMs在HMs中的诊疗潜力以及在HMs临床诊疗应用之前面临的未来挑战。